Cisplatin Resistance: Genetic and Epigenetic Factors Involved
Cisplatin (CDDP) is the drug of choice against different types of cancer. However, tumor cells can acquire resistance to the damage caused by cisplatin, generating genetic and epigenetic changes that lead to the generation of resistance and the activation of intrinsic resistance mechanisms in cancer...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-09-01
|
| Series: | Biomolecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2218-273X/12/10/1365 |
| _version_ | 1797474911837487104 |
|---|---|
| author | Yuliannis Lugones Pía Loren Luis A. Salazar |
| author_facet | Yuliannis Lugones Pía Loren Luis A. Salazar |
| author_sort | Yuliannis Lugones |
| collection | DOAJ |
| description | Cisplatin (CDDP) is the drug of choice against different types of cancer. However, tumor cells can acquire resistance to the damage caused by cisplatin, generating genetic and epigenetic changes that lead to the generation of resistance and the activation of intrinsic resistance mechanisms in cancer cells. Among them, we can find mutations, alternative splicing, epigenetic-driven expression changes, and even post-translational modifications of proteins. However, the molecular mechanisms by which CDDP resistance develops are not clear but are believed to be multi-factorial. This article highlights a description of cisplatin, which includes action mechanism, resistance, and epigenetic factors involved in cisplatin resistance. |
| first_indexed | 2024-03-09T20:37:43Z |
| format | Article |
| id | doaj.art-35ad18ee46bd456ab35c63d98500fa87 |
| institution | Directory Open Access Journal |
| issn | 2218-273X |
| language | English |
| last_indexed | 2024-03-09T20:37:43Z |
| publishDate | 2022-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomolecules |
| spelling | doaj.art-35ad18ee46bd456ab35c63d98500fa872023-11-23T23:07:28ZengMDPI AGBiomolecules2218-273X2022-09-011210136510.3390/biom12101365Cisplatin Resistance: Genetic and Epigenetic Factors InvolvedYuliannis Lugones0Pía Loren1Luis A. Salazar2Doctoral Programme in Sciences with Major in Applied Cellular and Molecular Biology, Universidad de La Frontera, Temuco 4811230, ChileCenter of Molecular Biology and Pharmacogenetics, Scientific and Technological Bioresource Nucleus, Universidad de La Frontera, Temuco 4811230, ChileCenter of Molecular Biology and Pharmacogenetics, Scientific and Technological Bioresource Nucleus, Universidad de La Frontera, Temuco 4811230, ChileCisplatin (CDDP) is the drug of choice against different types of cancer. However, tumor cells can acquire resistance to the damage caused by cisplatin, generating genetic and epigenetic changes that lead to the generation of resistance and the activation of intrinsic resistance mechanisms in cancer cells. Among them, we can find mutations, alternative splicing, epigenetic-driven expression changes, and even post-translational modifications of proteins. However, the molecular mechanisms by which CDDP resistance develops are not clear but are believed to be multi-factorial. This article highlights a description of cisplatin, which includes action mechanism, resistance, and epigenetic factors involved in cisplatin resistance.https://www.mdpi.com/2218-273X/12/10/1365cancercisplatindrug resistanceepigenetics |
| spellingShingle | Yuliannis Lugones Pía Loren Luis A. Salazar Cisplatin Resistance: Genetic and Epigenetic Factors Involved Biomolecules cancer cisplatin drug resistance epigenetics |
| title | Cisplatin Resistance: Genetic and Epigenetic Factors Involved |
| title_full | Cisplatin Resistance: Genetic and Epigenetic Factors Involved |
| title_fullStr | Cisplatin Resistance: Genetic and Epigenetic Factors Involved |
| title_full_unstemmed | Cisplatin Resistance: Genetic and Epigenetic Factors Involved |
| title_short | Cisplatin Resistance: Genetic and Epigenetic Factors Involved |
| title_sort | cisplatin resistance genetic and epigenetic factors involved |
| topic | cancer cisplatin drug resistance epigenetics |
| url | https://www.mdpi.com/2218-273X/12/10/1365 |
| work_keys_str_mv | AT yuliannislugones cisplatinresistancegeneticandepigeneticfactorsinvolved AT pialoren cisplatinresistancegeneticandepigeneticfactorsinvolved AT luisasalazar cisplatinresistancegeneticandepigeneticfactorsinvolved |